BioSpace News Archive

Passage Bio, Inc. reported financial results for the third quarter ended September 30, 2023, and provided recent business highlights.

Atea Pharmaceuticals, Inc. announced the presentation of two posters supporting the combination of bemnifosbuvir, an oral nucleotide polymerase inhibitor, and ruzasvir, an oral NS5A inhibitor, as a potential treatment for Hepatitis C Virus at the American Association for the Study of Liver Diseases’ The Liver Meeting 2023, being held from November 10-14, 2023 in Boston, MA.

Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia and Long-COVID, announced financial results for the third quarter ended September 30, 2023.

Tango Therapeutics, Inc. announced that two abstracts have been selected for poster presentations at the Society for Neuro-Oncology 28th Annual Meeting taking place November 15-19, 2023, in Vancouver, Canada.

Tonix Pharmaceuticals Holding Corp. announced that the first participant was enrolled in an investigator-initiated Phase 2 study of TNX-1900 for improving bone health in children with autism spectrum disorder, named the BOX study, at Massachusetts General Hospital.

Acumen Pharmaceuticals, Inc. announced that it has entered into a senior secured loan and security agreement with K2 HealthVentures, a healthcare-focused specialty finance company.

ViaNautis Bio, a groundbreaking nanomedicine company at the forefront of genetic therapies, is excited to announce the successful completion of its Series A funding round, raising $25 million.

Biovica International announces that the company has signed a commercial partnership agreement for the Nordics with Axlab A/S to commercialize the DiviTum® TKa assay.

FluoGuide A/S announced positive topline efficacy and safety results in the phase IIb trial with the lead product FG001 for guiding surgery in aggressive brain cancer.

Nucleome Therapeutics announces the appointment of Dr Stephen Harrison as Chief Scientific Officer, effective immediately.